Discovery services contractor Reaction Biology has further expanded its executive team, framing the appointments as the next phase of the firm’s development.
Reaction named Alan Findlater as chief commercial officer and Emily Doyle as chief people officer this week. In his new role, Findlater will support Reaction’s strategic commercial objectives along with its integrated commercial architecture and will oversee the business development, client services and sales functions, a spokesperson told Fierce Biotech.
Findlater previously worked at contractors including Vium, Charles River Laboratories and WIL Research Technologies. He also has experience in pharma gained during his time at Johnson & Johnson and Smith & Nephew Pharmaceuticals.
Most recently, Findlater was CCO at biological specimens and services firm BioIVT, with responsibility for global commercial strategy.
As chief people officer, Doyle will oversee talent acquisition and administration, leadership development, compensation and benefits as well as the development of diversity and inclusion policy. Doyle’s previous roles have included vice president of global human resources at Globus Medical and head of human resources at AstraZeneca’s diabetes franchise. She has also worked as chief human resource officer at Strongbridge BioPharma.
Prior to joining Reaction, Doyle served as senior vice president of human resources at Inzen Therapeutics.
Both these roles have been newly created at Reaction, the spokesperson said.
The appointments are the latest additions Reaction has made to its executive team. In April, former Strongbridge BioPharma President and Chief FInancial Officer Richard Kollender was hired as CFO and chief business officer.
In February, Reaction launched a drug discovery platform comprising target research, hit identification, hit-to-lead and lead optimization services. The platform was created in partnership with Netherlands-based Symeres and China-headquartered PharmaCore Labs.